India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the ...

Sun Pharmaceutical Industries Ltd. closed 14.19% short of its 52-week high of 1,960.20 rupees, which the company reached on ...

Sun Pharmaceutical Industries Ltd. closed 15.15% short of its 52-week high of 1,960.20 rupees, which the company achieved on ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

Sun Pharmaceutical Industries, announced its release of Leqselvi in the U.S. earlier this week. Leqselvi™ is currently ...

In a regulatory filing on Monday, Sun Pharma announced that it has reached a settlement and licensing agreement with Incyte ...

The market needs to reclaim and sustain above the 20-day EMA to witness a further northward journey in the upcoming sessions.

A Sun Pharmaceutical plant in India that has been repeatedly cited by the FDA for serious quality control issues failed ...

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

President Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month, starting with a "low ...

The FDA cracked down on two plants in India and one in Korea in separate recently released reports, citing issues ranging ...